Legionella infection causes 2 to 14% of community-acquired pneumonia (CAP). Legionella micdadei constitutes <1% of these infections. We describe a case of cavitary L. micdadei CAP in a myeloma patient receiving thalidomide treatment. The importance of considering pneumonia and problems in diagnosing pneumonia caused by L. micdadei in this patient population are reviewed.
Since the initial blood cultures and respiratory samples were culture negative, the infectious disease service was consulted. Vancomycin therapy was discontinued, and azithromycin therapy was started. Test results for legionella urine antigen were negative. Transthoracic needle aspiration of the lesion and chest tube drainage of the effusion were performed. The effusion was exudative, with a lactate dehydrogenase level of 2,450 IU/liter. Modified acid-fast staining (7) tests of BAL fluid and lung aspirate were requested by the infectious diseases service. Both samples were positive for small coccobacilli with this stain (Fig. 2) , and cultures subsequently grew Legionella micdadei (confirmed with partial 16S rRNA gene sequencing).
The patient improved within 6 to 7 days after the initiation of azithromycin therapy and made a complete recovery. Due to the family syndrome, which was similar to Pontiac fever, further questioning identified the use of a portable humidifier that was rarely cleaned. Samples of legionella culture taken from the humidifier were sent to a reference water testing laboratory, but results were reported as unreliable due to an overgrowth of multiple bacteria in the sample. Testing of the home water system was not performed.
Legionella infections cause 2 to 14% of community-acquired pneumonia (CAP) (4, 28, 30) . In a recent study, Legionella micdadei was present in less than 1% of cases of communityacquired pneumonia (32) . L. micdadei is more commonly identified as the cause of nosocomial pneumonia (18, 26) . Cavitary pneumonia is reported in transplant patients (9, 12, 21) or human immunodeficiency virus (HIV)-infected individuals (15, 24) . In a case series of renal transplant recipients with L. micdadei pneumonia, 18.5% (5 of 27) of the patients developed a lung abscess (29) . There is one previous case of L. micdadei infection described in a patient with multiple myeloma (19) and one case of nosocomial L. micdadei pulmonary abscess and empyema formation reported in a nontransplant patient (13) .
This case is unique in that we describe the first case of community-acquired cavitary L. micdadei pneumonia in a patient whose only known risks were underlying myeloma and the use of low-dose prednisone. More importantly, there are no other cases in the literature that describe L. micdadei infection in the setting of thalidomide therapy for multiple myeloma. Thalidomide and its immunomodulatory analogues are being used increasingly to treat malignancies (2) and for the treatment of other diseases (11) . Thalidomide has been associated previously with lung toxicity (5), which may in itself predispose patients to pulmonary infections. Whether the use of this drug alone or in combination with steroids increases the risk of opportunistic infections remains to be proven. However, Nocardia farcinica infection has been reported in patients receiving thalidomide during treatment for leprosy (1), and Pneumocystis pneumonia has been reported in patients receiving thalidomide in combination with temozolomide (20) .
This case also demonstrates some of the pitfalls in diagnosing legionellosis. It is important to note that the urinary antigen test only reliably detects Legionella pneumophila serogroup 1, and many commercial direct-fluorescent antigen kits detect only Legionella pneumophila species. Thus, the use of culture or nucleic acid detection methods is required to definitively diagnose infection with legionella strains other than L. pneumophila. In this case, the findings of coccobacilli in the modi- On presentation, the patient was bradycardic. Bradycardia is reported in patients with legionella infections (14) . In this case, there was preexisting evidence of bradycardia prior to the development of pneumonia. Thalidomide used for the treatment of myeloma has been associated with bradycardia in up to 50% of cases (10) . There is at least a theoretical risk that the fluoroquinolones and thalidomide could interact to worsen bradycardia (8, 17, 23) . While current evidence supports fluoroquinolones as the first-line therapy for treating Legionella pneumonia (3, 22, 27) , due to this patient's allergy to fluoroquinolones, azithromycin was used, with a complete response.
We suspect the source of infection was the home humidifier. Family members described an acute febrile illness that occurred at the same time that our patient became sick. Transmission of legionella from humidification systems has been documented previously (16, 25, 31, 33) . There are specific recommendations to prevent nosocomial legionellosis in bone marrow transplantation patients (6) . It may also be wise to advise other immunocompromised patients about the risks of and appropriate measures to prevent infection with legionella.
This is the first case of a lung abscess caused by L. micdadei described in a patient receiving thalidomide for refractory myeloma. The probable source of infection was a portable home humidifier. Whether the use of thalidomide in the treatment of myeloma predisposes these patients to legionellosis and other opportunistic infections remains to be determined. Legionellosis including non-L. pneumophila species should be considered as a possible cause of pulmonary abscess, even in ambulatory immunosuppressed patients.
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